Abstract
Introduction

Idiopathic CD4+ T-lymphocytopenia (ICL) is a rare syndrome that was first reported in 1992 by the Centers for Disease Control and Prevention (CDC) of the USA (1). In the same year, a similar case was also reported in Japan (2). This disease is characterized by an absolute decrease in CD 4+ T lymphocyte count to less than 300/μL or to less than 20% of total T lymphocytes without evidence of human immunodeficiency virus-1 (HIV-1), HIV-2, human T-cell leukemia virus type-1 (HTLV-1), or HTLV-2 infection, a known immunodeficiency syndrome, or therapy-related CD4+ Tlymphocyte depression (3-8). ICL is a cluster of heterogeneous diseases with diverse clinical courses and immunologic characteristics. Although some patients present with opportunistic infections such as cryptococcosis, human papillomavirus (HPV), and nontuberculous mycobacteria, others remain in a relatively healthy condition for years
 (8) 
Discussion
In a nationwide study of ICL in the USA, 57 patients were recruited between 1992 to 2006 (8). Eighteen patients were excluded from the study because they did not fulfill the criteria for the definition of ICL (1, 5). The excluded patients had a CD4 T-lymphocyte count of more than 300/μL, HIV antibody, or were complicated with hematological malignancies that could have caused lymphocytopenia (8). One patient was excluded because of an alternative diagnosis
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(common variable immunodeficiency). The present patient does not meet the criteria for any known immunodeficiency diseases other than ICL. Severe combined immunodeficiency (SCID) was ruled out, and humoral immunodeficiencies such as common variable immunodeficiency and hyper-IgM syndrome were also ruled out because of his normal immunoglobulin class levels. Wiskott-Aldrich syndrome and ataxia telangiectasia were ruled out by the absence of their characteristic clinical features and laboratory data.
ICL usually occurs in middle-aged or elderly adults, and the number of patients aged from 20 to 30 years old in the cohort study was only 2 out of 39 cases (5.1%), and there were no patients younger than 20 years old (8) . The present patient met the criteria for ICL from age 9. Childhood ICL cases are rare although there have been a few reports (9, 10) . There is no common feature of childhood ICL, and there is heterogeneity even within childhood cases; two cases showed IgA deficiency with progressive pulmonary infection and another case showed a significant increase in γδTCR-bearing T cells (9, 10 (11) . Autoimmunity is also common in ICL, and 9 patients (23.1%) developed autoimmune diseases in the cohort study, either before diagnosis or in the follow-up period (8) . One patient developed autoimmune hemolytic anemia, as in our patient, but no patient de- 
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